Preparing healthcare companies for success
in the value-based economy

New Access Meter Report
NOW AVAILABLE

more info >

Solutions

Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >

Insights

Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

News and Events

Panel: Drug Pricing and Value Based Reimbursement

Jeff Berkowitz

Real Endpoints

Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors -- about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.

October 13, 2019 -
October 15, 2019

Laguna Beach, CA

Real-World Noise, Trends, Realities, and Implications on the Road to Value-Based Contracting in Cancer Care

Speaker: Jeff Berkowitz
Roger Longman

Real Endpoints

Value-based pharma contracts have been rare in oncology relative to other therapeutic categories — and for a variety of good and bad reasons. But in the hyper-competitive future, risk-sharing will become a necessary component in every oncology company’s strategic toolkit. In five separate sessions at the value-based cancer summit in NY Oct 16-18, Real Endpoints CEO Jeff Berkowitz and Chairman Roger Longman will help lay out the challenges and the unexploited opportunities in oncology VBAs

October 16, 2019 -
October 18, 2019

New York, NY

event >

Real Endpoints: Research supports expanding insurance coverage of non-invasive prenatal testing

by University of Colorado

Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), to women under the age of 35. It represents a first-of-its-kind published analysis of results from a risk-sharing agreement between biotechnology company Illumina, Inc. and insurer Harvard Pilgrim Health Care, conducting the research in partnership with advisory firm Real Endpoints to evaluate the impacts of the agreement.

October 8, 2019

EurekAlert

read full press release >

Recent Insights

view archive >

June 11, 2019

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. Payers are open to innovative financing models that improve financial predictability and reward clinical performance.

read full insight article >

February 13, 2019

Examining New Payment Ideas for Curative Therapies

How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."

read full insight article >